<DOC>
	<DOC>NCT00523042</DOC>
	<brief_summary>This trial is conducted in Europe, Asia, Oceania and the United States of America (USA). This is a one-year clinical trial to compare the safety of inhaled preprandial human insulin to subcutaneous insulin aspart in subjects with type 1 or 2 diabetes and asthma.</brief_summary>
	<brief_title>Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma</brief_title>
	<detailed_description>The decision to discontinue the development of AERxÂ® is not due to any safety concerns. An analysis concluded that fast-acting inhaled insulin in the form it is known today, is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Type 1 or type 2 diabetes Treatment with insulin and/or oral antidiabetic drugs Asthma for at least 6 months Positive airway reversibility/bronchoprovocation test or documented positive test in the last 3 years HbA1C less than or equal to 11.0 % Body Mass Index (BMI) less than or equal to 40.0 kg/m2 Current smoking or smoking within the last 6 months Other current acute or chronic pulmonary disease excluding asthma Recurrent severe hypoglycaemia Proliferative retinopathy or maculopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>